236 related articles for article (PubMed ID: 26633034)
1. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).
Fujiwara Y; Kobayashi S; Nagano H; Kanai M; Hatano E; Toyoda M; Ajiki T; Takashima Y; Yoshimura K; Hamada A; Minami H; Ioka T
PLoS One; 2015; 10(12):e0143072. PubMed ID: 26633034
[TBL] [Abstract][Full Text] [Related]
2. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Toyoda M; Ajiki T; Fujiwara Y; Nagano H; Kobayashi S; Sakai D; Hatano E; Kanai M; Nakamori S; Miyamoto A; Tsuji A; Kaihara S; Ikoma H; Takemura S; Toyokawa H; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1295-301. PubMed ID: 24614947
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Kobayashi S; Nagano H; Sakai D; Eguchi H; Hatano E; Kanai M; Seo S; Taura K; Fujiwara Y; Ajiki T; Takemura S; Kubo S; Yanagimoto H; Toyokawa H; Tsuji A; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Oct; 74(4):699-709. PubMed ID: 25074036
[TBL] [Abstract][Full Text] [Related]
7. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
Yamanaka K; Hatano E; Kanai M; Tanaka S; Yamamoto K; Narita M; Nagata H; Ishii T; Machimoto T; Taura K; Uemoto S
Int J Clin Oncol; 2014; 19(3):485-9. PubMed ID: 23765238
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
[TBL] [Abstract][Full Text] [Related]
12. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer.
Mori S; Aoki T; Shiraki T; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Sakuraoka Y; Iso Y; Kubota K
Anticancer Res; 2021 Oct; 41(10):5231-5240. PubMed ID: 34593476
[TBL] [Abstract][Full Text] [Related]
15. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
16. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
Eng C; Ramanathan RK; Wong MK; Remick SC; Dai L; Wade-Oliver KT; Mani S; Kindler HL
Am J Clin Oncol; 2004 Dec; 27(6):565-9. PubMed ID: 15577433
[TBL] [Abstract][Full Text] [Related]
17. Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Morine Y; Shimada M; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Imura S
Anticancer Res; 2017 Nov; 37(11):6421-6428. PubMed ID: 29061828
[TBL] [Abstract][Full Text] [Related]
18. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer.
Kobayashi S; Tomokuni A; Gotoh K; Takahashi H; Akita H; Marubashi S; Yamada T; Teshima T; Fukui K; Fujiwara Y; Sakon M
Eur J Surg Oncol; 2017 Apr; 43(4):763-771. PubMed ID: 28100416
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
